Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.85 |
| ▸ | RAMP1 | O60894 | 15/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15227820 | 0.93 | CALCRL (0.74) | CALCRLRAMP1 | |
| SCHEMBL15228057 | 0.93 | CALCRL (0.74) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL30596427 | 0.92 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL29373722 | 0.92 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL20784253 | 0.92 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL31610892 | 0.92 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL3698428 | 0.92 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL22259356 | 0.92 | CALCRL (1.00) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL30416212 | 0.91 | CALCRL (0.99) | CALCRLRAMP1 | |
| Ubrogepant SCHEMBL16653012 | 0.91 | CALCRL (0.99) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637656-B1 | N-Piperidinone-indane carboxamides as CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9499541-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499541-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150031716-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150031716-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-01-29 | — | — | US | disclosed |
| US-8883807-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883807-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| WO-2012064911-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 29/4885 |
| US-20150031716-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.